HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
Michael Roche(The University of Melbourne), Paul R. Gorry(RMIT University), Sharon R. Lewin(Peter Doherty Institute), Martin R. Jakobsen(Aarhus University), Benhur Lee(Icahn School of Medicine at Mount Sinai), Mike Westby(Pfizer (United States)), Melissa J. Churchill(Monash University), Hamid Salimiseyedabad(Burnet Institute), Anne Ellett(Monash University), Becky Jubb(Pfizer (United States))
Cited by 42
Related Papers
Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection
|The Journal of Infectious Diseases|2011|1.1k
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
|Molecular Cell|2018|663
Immune checkpoint blockade in infectious diseases
|Nature reviews. Immunology|2017|571